[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369061-105":59,"doc-detail-369061-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-specific-pharmacogenomics-demonstrates-xct-as-predictive-therapeutic-target-in-colon-cancer","Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer","","Patient-specific pharmacogenomics integrates cellular and molecular profiles from individual colorectal cancer patients to support diagnosis, prognosis, and therapy selection. The study performs comparative mRNA-seq on tumor and adjacent healthy tissues from 32 CRC patients, identifying dysregulated metabolic programs and highlighting the overexpressed SLC7A11 (xCT) and SLC3A2 components of the cystine/glutamate Xc- system. Functional CRISPR perturbation and assays in five patient-derived organoid models reveal an uncharacterized cell-surface protein signature linked to chemotherapy resistance and support pharmacological blockade of ferroptosis as a therapeutic strategy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-specific-pharmacogenomics-demonstrates-xct-as-predictive-therapeutic-target-in-colon-cancer/369061/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-specific-pharmacogenomics-demonstrates-xct-as-predictive-therapeutic-target-in-colon-cancer/369061.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What patient-level data did the study use to analyze colorectal cancer?","Question",{"text":112,"@type":113},"It integrated cellular and molecular data from individual patients, using comparative mRNA-seq on tumor tissues paired with adjacent healthy tissues from 32 CRC patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which molecular target and pathway were emphasized as predictive in colon cancer?",{"text":117,"@type":113},"The study focused on SLC7A11 (xCT) and SLC3A2, which form the cystine/glutamate transporter (Xc-) system.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the researchers test the oncogenic and therapeutic relevance of the target?",{"text":121,"@type":113},"They combined CRISPR screen perturbation analysis across multiple cell types with functional assays in five primary patient-derived organoid models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369061,1790378605,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Patient-speciﬁc pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity  \nMarco Strecker 1 , Keren Zohar2, Martin B€ottcher3, Thomas Wartmann2, Henry Freudenstein 1, Maximilian Doelling 1, Mihailo Andric 1, Wenjie Shi 1, Or Kakhlon4,5, Katrin Hippe6, Beatrix Jahnke7, Dimitrios Mougiakakos3, Franziska Baenke7,8, Daniel Stange7,8, Roland S. Croner 1, Michal Linial2 and Ulf D. Kahlert 1,9   \n1 Molecular and Experimental Surgery, Clinic for Visceral- , General, Vascular and Transplantation Surgery, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Magdeburg, Germany  \n2 Department of Biological Chemistry, Faculty of Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel  \n3 Clinic for Hematology and Oncology, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Magdeburg, Germany  \n4 Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel  \n5 Faculty of Medicine, The Hebrew University of Jerusalem, Israel  \n6 Institute for Pathology, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Magdeburg, Germany  \n7 Department of Surgery, University Medical Center Dresden, Dresden, Germany  \n8 National Center for Tumour Diseases Dresden (NCT/UCC), a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden – Rossendorf (HZDR), Dresden, Germany  \n9 Research Campus Stimulate, University of Magdeburg, Magdeburg, Germany  \nKeywords  \nchemotherapy resistance; ferroptosis; patient-derived organoids; tumor metabolism; xCT  \nCorrespondence  \nU. D. Kahlert, Molecular and Experimental Surgery, Clinic for Visceral- , General, Vascular and Transplantation Surgery, University Medicine Magdeburg, Otto-von Guericke University Magdeburg, Germany E-mail: [ulf.kahlert@med.ovgu.de](ulf.kahlert@med.ovgu.de)  \nMarco Strecker, Keren Zohar, Michal Linialand Ulf D. Kahlert contributed equally to this work.  \n(Received 9 April 2025, revised 14 August 2025, accepted 10 September 2025, available online 24 September 2025)  \ndoi:10 . 1002/1878-0261 .70129  \nColorectal cancer (CRC) represents the third leading cause of cancer-related deaths. Integrating cellular and molecular data from individual patients has become valuable for diagnosis, prognosis, and treatment selection. Here, we present a comparative mRNA-seq analysis of tissue samples from 32 CRC patients, pairing tumors with adjacent healthy tissues. Differential expression gene (DEG) analysis revealed dysregulated metabolic programs. We focused on the impact of overexpressed SLC7A11 (xCT) and SLC3A2, which compose the cystine/glutamate transporter (Xc-) system. To assess the oncogenic potential ofthe Xc-system, we analyzed gene perturbations from CRISPR screens across various cell types and used functional assays in ﬁve primary patient-derived organoid models. We identiﬁed a previously uncharacterized cell surface protein signature predicting chemotherapy resistance and highlighted the causality and potential of pharmacological blockage offerroptosis as a promising avenue for cancer therapy. Redox homeostasis, ion/amino acid transporters, and regulators of neuronal survival and differentiation were pathways associated with these co-dependent genes in patient specimens. This study highlights several potential clinical targets for CRC therapy and promotes the use of patient-derived organoids oids to functionally validate in silico predictions.  \nAbbreviations  \nCD44v, CD44 variant; COAD, colorectal adenocarcinoma; CPM, counts per million; CRC, colorectal cancer; DEG, differential expression of gene; DEM, differential gene expression of miRNA; EMT, epithelial–mesenchymal transition; FC, fold change; GO, gene ontology;  \nGPX, glutathione peroxidases; GSH, glutathione; GTEx, genotype-tissue expression","cbCaikux3QwQZYRs","https://ap.wps.com/l/cbCaikux3QwQZYRs","pdf",2623968,"English","# Introduction\n## Patient-specific data integration for CRC biomarkers\n## Targeting the Xc- system (SLC7A11/xCT and SLC3A2)\n## Predicting chemotherapy resistance with organoid validation","[{\"question\":\"What patient-level data did the study use to analyze colorectal cancer?\",\"answer\":\"It integrated cellular and molecular data from individual patients, using comparative mRNA-seq on tumor tissues paired with adjacent healthy tissues from 32 CRC patients.\"},{\"question\":\"Which molecular target and pathway were emphasized as predictive in colon cancer?\",\"answer\":\"The study focused on SLC7A11 (xCT) and SLC3A2, which form the cystine/glutamate transporter (Xc-) system.\"},{\"question\":\"How did the researchers test the oncogenic and therapeutic relevance of the target?\",\"answer\":\"They combined CRISPR screen perturbation analysis across multiple cell types with functional assays in five primary patient-derived organoid models.\"}]","Patient-specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer | PDF",1790180448,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bebb656928c3242cfe5b072374753da5.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2bb1017da74585ee5a2e27c399b03612.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7314147217d17f141db4b248e3f57378.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6ba4767b56fb17c28e14ec599d0a26a.webp",980,1287]